Juan Pablo Alderuccio, MD

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.

A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.

A panelist discusses how managing relapsed/refractory follicular lymphoma (R/R FL) requires carefully weighing multiple factors including patient fitness, prior therapies, duration of response, symptoms, and treatment goals while confronting challenges like treatment resistance, cumulative toxicities, and the lack of a clear standard of care sequence.